BioMed Research International

Biotechnological Drugs: The Breakthrough in Autoimmune Rheumatic Conditions


Publishing date
06 Jun 2014
Status
Published
Submission deadline
17 Jan 2014

Lead Editor

1Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, viale Golgi 2, 27100 Pavia, Italy

2Sections of Rheumatology and Pulmonary Medicine, Department of Medicine, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA, USA

3Division of Rheumatology, University Hospital Mainz and ACURA Rheumatology Center Rhineland-Palatinate, Kaiser-Wilhelm Street 9-11, 55543 Bad Kreuznach, Germany


Biotechnological Drugs: The Breakthrough in Autoimmune Rheumatic Conditions

Description

Biotechnological drugs are a wide group of therapeutic agents obtained by means of genetic engineering methodologies. They act through the inhibition of specific cytokines/cells involved in the cascade of different pathological processes, leading to the modification of host immune response. The main targets of these drugs are TNF-alpha, IL-6, IL-1, and B and T cells. In the latest years, according to the improved knowledge in the pathogenesis of several diseases, the use of these drugs is steadily increasing, and new agents have been marketed or are under development.

Autoimmune rheumatic diseases are the prototypical example of pathological conditions that may benefit from these therapies. Biotechnological drugs deeply improved the prognosis and quality of life of patients affected by rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; moreover positive effects have been described also in connective tissue diseases and gout. Despite the large number of papers published and the large clinical experience obtained for some of these drugs, there are still many questions on this topic that should be clarified.

This issue will focus on original manuscripts evaluating the unmet needs of marketed biotechnological drugs in autoimmune rheumatic conditions. Reviews will be limited to peculiar diseases/clinical aspects that may really help clinicians in the daily practice. Papers focusing on drugs under development or experimentation are encouraged. Potential topics include, but are not limited to:

  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Systemic lupus erythematosus
  • Idiopathic inflammatory myopathies
  • Gout

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/immunology/bd/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2014
  • - Article ID 481973
  • - Editorial

Biotechnological Drugs: The Breakthrough in Autoimmune Rheumatic Conditions

Lorenzo Cavagna | Lesley-Ann Saketkoo | ... | Roberto Caporali
  • Special Issue
  • - Volume 2014
  • - Article ID 416892
  • - Research Article

Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry

Matteo Filippini | Chiara Bazzani | ... | Roberto Gorla
  • Special Issue
  • - Volume 2014
  • - Article ID 831603
  • - Review Article

Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs

Ennio Giulio Favalli | Serena Bugatti | ... | Roberto Caporali
  • Special Issue
  • - Volume 2014
  • - Article ID 264859
  • - Review Article

The Emerging Role of Biotechnological Drugs in the Treatment of Gout

L. Cavagna | W. J. Taylor
  • Special Issue
  • - Volume 2014
  • - Article ID 675108
  • - Clinical Study

Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF- and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab

Martin Schulz | Helmut Dotzlaw | Gunther Neeck
  • Special Issue
  • - Volume 2014
  • - Article ID 860651
  • - Review Article

Adipokines, Biomarkers of Endothelial Activation, and Metabolic Syndrome in Patients with Ankylosing Spondylitis

Fernanda Genre | Raquel López-Mejías | ... | Miguel A. González-Gay
  • Special Issue
  • - Volume 2014
  • - Article ID 325875
  • - Research Article

Attenuation of Collagen-Induced Arthritis in Rat by Nicotinic Alpha7 Receptor Partial Agonist GTS-21

Yiping Hu | Ruoxi Liu | ... | Peng Zhang
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit